Clinical Scorecard: Evaluation of Bone Marrow Hemodilution Impact on Measurable Residual Disease in Multiple Myeloma Using Next Generation Flow Cytometry: A Brief Review
At a Glance
Category
Detail
Condition
Key Mechanisms
Bone marrow hemodilution affects measurable residual disease (MRD) assessment, potentially leading to false negatives and misinterpretation of treatment efficacy.
Target Population
Care Setting
Key Highlights
Standardized approaches for estimating and interpreting hemodilution are currently lacking.
Guideline-Based Recommendations
Diagnosis
Utilize NGF and NGS for MRD identification.
Assess hemodilution using a combination of cellular populations, including mast cells, NRBC, and BCP.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients diagnosed with Multiple Myeloma.
Treatment can significantly influence cellular populations used for hemodilution assessment.
Clinical Best Practices
Employ a multiparametric approach for evaluating hemodilution, incorporating mast cells, NRBC, and BCP.
